# Nanophoria S.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanophoria-s-r-l

- Industry: Biotechnology
- Headquarters: Milan, Italy
- Website: www.nanophoria.com
- Total disclosed funding: $101M
- Latest round: Series A (Jan 20, 2026)
- Investors on record: 5

## About

Based in Milano, Italy, and founded in 2022 by CEO Claudio De Luca, Michele Lafisco, Daniele Catalucci, and Alessio Alogna, Nanophoria S.R.L., a.k.a. NanoPhoria is a pre-clinical stage biotech company that is developing non-viral drug delivery platform based on inorganic nanoparticles. In January 2026, Nanophoria S.r.l. raised EUR 15 million in series A funding from investor European Innovation Council. The round was part of a larger EUR 83.5 million series A funding.

NanoPhoria’s core technology is a non-viral, nano-in-micro delivery platform designed for inhalable administration of biologics. The company’s lead product candidate, NP-MP1, is being developed for the treatment of heart failure with reduced ejection fraction (HFrEF), a serious and debilitating condition affecting millions of patients worldwide. At the molecular level, HFrEF is associated with dysregulation of L-type calcium channels in cardiomyocytes, which play a central role in cardiac contractility. The active principle of NP-MP1 is a proprietary mimetic peptide designed to modulate intracellular mechanisms involved in calcium channel trafficking. Preclinical studies in small and large animal models have demonstrated the peptide’s ability to regulate L-type calcium channel localization and function within cardiomyocytes, supporting its potential classification as a disease-modifying therapy. NP-MP1 is formulated as a three-level inhalable dry powder. The mimetic peptides are first encapsulated in calcium-phosphate nanoparticles, which are then embedded within lung-compatible, mannitol-based microparticles. Upon inhalation, the microparticles reach the deep lung, dissolve in the alveolar space, and release peptide-loaded nanoparticles into the bloodstream. These nanoparticles subsequently reach the heart, where they are taken up by cardiomyocytes, enabling intracellular release of the peptide and restoration of physiological calcium channel function.

The company will use the January 2026 funding to move its main drug candidate through required pre-clinical studies and early human testing.

## Funding rounds

- Series A, Jan 20, 2026, $17M — European Innovation Council
- Series A, Oct 6, 2025, $80M — Sofinnova Partners, CDP Venture Capital, Panakes Partners, XGEN Venture
- Seed, May 12, 2022, $3.6M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A
- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series A
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series A
- XGEN Venture (https://capitalatlas.ai/funds/xgen-venture) — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A